Business Description
Viatris Inc
NAICS : 325411
SIC : 2833
ISIN : US92556V1061
Compare
Compare
Traded in other countries / regions
VTRS.USA0A5V.UKVIA.GermanyMYL.MexicoMYL.AustriaMYL1.SwitzerlandMYL.Israel IPO Date
2015-11-04Description
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.89 | |||||
| Debt-to-EBITDA | 3.07 | |||||
| Interest Coverage | 1.76 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.03 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -15.7 | |||||
| 3-Year EBITDA Growth Rate | 0.5 | |||||
| 3-Year EPS without NRI Growth Rate | -26.8 | |||||
| 3-Year FCF Growth Rate | -8.7 | |||||
| 3-Year Book Growth Rate | -9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -0.66 | |||||
| Future 3-5Y Total Revenue Growth Rate | -2.57 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | 33.85 | |||||
| 12-1 Month Momentum % | 5.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.23 | |||||
| Days Inventory | 139.59 | |||||
| Days Sales Outstanding | 72.93 | |||||
| Days Payable | 46.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -33 | |||||
| Shareholder Yield % | 28.4 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 39.55 | |||||
| Operating Margin % | 6.61 | |||||
| Net Margin % | 11.84 | |||||
| FCF Margin % | 13.08 | |||||
| ROE % | 8.9 | |||||
| ROA % | 3.73 | |||||
| ROIC % | 1.69 | |||||
| ROC (Joel Greenblatt) % | 46.72 | |||||
| ROCE % | 7.3 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 6.21 | |||||
| Forward PE Ratio | 3.29 | |||||
| PE Ratio without NRI | 6.21 | |||||
| Shiller PE Ratio | 9.99 | |||||
| Price-to-Owner-Earnings | 3.24 | |||||
| PS Ratio | 0.73 | |||||
| PB Ratio | 0.54 | |||||
| Price-to-Free-Cash-Flow | 5.58 | |||||
| Price-to-Operating-Cash-Flow | 4.59 | |||||
| EV-to-EBIT | 9.13 | |||||
| EV-to-EBITDA | 4.67 | |||||
| EV-to-Revenue | 1.83 | |||||
| EV-to-FCF | 13.99 | |||||
| Price-to-Projected-FCF | 0.34 | |||||
| Price-to-Median-PS-Value | 0.52 | |||||
| Earnings Yield (Greenblatt) % | 10.96 | |||||
| FCF Yield % | 18 | |||||
| Forward Rate of Return (Yacktman) % | 18.17 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Viatris Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₪) | 57,243.584 | ||
| EPS (TTM) (₪) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (₪) | 0 | ||
| 20-Day SMA (₪) | 0 | ||
| 12-1 Month Momentum % | 5.13 | ||
| 52-Week Range (₪) | 105.2 - 168.4 | ||
| Shares Outstanding (Mil) | 536.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Viatris Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Viatris Inc Stock Events
| Event | Date | Price(₪) | ||
|---|---|---|---|---|
| No Event Data | ||||
Viatris Inc Frequently Asked Questions
What is Viatris Inc(XTAE:MYL)'s stock price today?
The current price of XTAE:MYL is ₪142.10. The 52 week high of XTAE:MYL is ₪168.40 and 52 week low is ₪105.20.
When is next earnings date of Viatris Inc(XTAE:MYL)?
The next earnings date of Viatris Inc(XTAE:MYL) is 2024-02-27 Est..
Does Viatris Inc(XTAE:MYL) pay dividends? If so, how much?
Viatris Inc(XTAE:MYL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers